SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN is trending amidst community discussions surrounding the potential rescheduling of cannabis and upcoming policy deadlines for hemp products, with enthusiasts highlighting its role as a culture-first cryptocurrency on Solana ahead of the 4/20 period. The narrative emphasizes its alignment with the broader cannabis movement and a long-term, patient investment approach.

Ethena

Ethena (ENA) is trending as the community eagerly discusses the massive $895 million PIPE financing secured by StablecoinX, earmarked for ENA token accumulation and buybacks, alongside the rapid growth of its USDe synthetic dollar. Further driving conversation are recent exchange listings and the continued accumulation by influential figures like Arthur Hayes, validating Ethena's expanding ecosystem.

Ethena is a delta-hedged synthetic dollar with native crypto yield derived from staking and perpetual funding rate

Ethena USDe

Ethena's USDe is actively discussed following a German regulatory order to wind down Ethena GmbH, compelling redemptions, even as the community also highlights its growing DeFi integrations, yield potential, and its connection to a proposed multi-entity fintech consolidation.

iShares Trust - iShares 0-3 Month Treasury Bond ETF

iShares 0-3 Month Treasury Bond ETF

Investors are increasingly turning to SGOV, the iShares 0-3 Month Treasury Bond ETF, as a secure 'cash parking' strategy amid broader market uncertainty and anticipation of a potential pullback. The community is actively touting its attractive 4-5% monthly yield and state tax exemption as a preferred low-risk alternative to traditional savings accounts and higher-volatility assets.

English version Introducing SWFTCoin (SWFTC) $SWFTC: Powering SWFT Blockchain and AI Services (SWFTGPT)  SwftCoin ($SWFTC) is the native utility token driving SWFT Blockchain's AI-powered ecosystem, SWFTGPT, and the first ever AI token featured on Coinbase. SWFTGPT is also the first domain-specific LLM for crypto.  SwftCoin key features include: 50% Reduced Transaction Fees: Lower costs on all transactions. AI Service Payments: Use $SWFTC to access SWFTGPT. Tools include expert market analysis,  predictions, and intelligent trading solutions.  Membership Benefits: Unlock premium features and AI agent services within SWFTGPT. AI-Powered Swaps: Enable precise, fast cross-chain transactions and analytics. SWFT Blockchain combines AI innovation with blockchain infrastructure, simplifying crypto trading while enhancing functionality through $SWFTC.   Chinese version $SWFTC：驱动 SWFT Blockchain 和 AI 服务（SWFTGPT） SwftCoin ($SWFTC) 是 SWFT Blockchain 的原生实用代币，为其 AI 驱动的生态系统 SWFTGPT 提供支持，同时也是 Coinbase 上首个 AI 代币。SWFTGPT 也是首个专注于加密领域的特定领域大型语言模型 (LLM)。 SwftCoin 的主要功能包括： 1、50% 交易费减免：降低所有交易成本。 2、AI 服务支付：使用 $SWFTC 访问 SWFTGPT 工具，包括专家市场分析、预测以及智能交易解决方案。 3、会员权益：解锁 SWFTGPT 的高级功能和 AI 代理服务。 4、AI 驱动的闪兑：实现精准快速的跨链交易和数据分析。 SWFT Blockchain 将 AI 创新与区块链基础设施结合，通过 $SWFTC 简化加密交易，并提升其功能性。

SwftCoin

SwftCoin (SWFTC) is trending with strong community interest, as investors eagerly eye a potential repeat of previous significant rallies, driven by its fully diluted token supply and its positioning as an undervalued, AI-integrated crypto exchange and cross-chain protocol. Many believe it is poised for substantial gains, drawing comparisons to other altcoin surges.

SSgA Active Trust - State Street Utilities Select Sector SPDR ETF

Utilities Select Sector SPDR Fund

The Utilities Select Sector SPDR Fund (XLU) is trending as a dual play, offering investors a defensive haven amid market uncertainty while also being a direct beneficiary of surging electricity demand from AI data centers. This dynamic is driving its strong price momentum, prompting community discussion on whether the sector's current valuation is sustainable or becoming overextended.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences is trending significantly due to reports that Eli Lilly is nearing a $1 billion acquisition, which many in the community consider a lowball offer for its innovative pipeline. This potential deal has sparked intense speculation about a bidding war, as other major pharmaceutical players are eager to secure Ventyx's leading NLRP3 inhibitor assets and their synergistic potential with GLP-1 therapies in the burgeoning inflammation and cardiometabolic markets.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending as its new CEO's strategic pivot to halt the company split and commit to substantial investment for growth has garnered support, igniting community discussions around its high dividend yield and perceived undervaluation against skepticism toward bearish analyst reports.

Wynn Resorts Ltd. is a holding company, which engages in the design, development, and operation of destination casino resorts. It operates through the following segments: Wynn Palace, Wynn Macau, Las Vegas Operations, Encore Boston Harbor, and Corporate and Other. The company was founded by Stephen Alan Wynn, Elaine P. Wynn, and Kazuo Okada in 2002 and is headquartered in Las Vegas, NV.

Wynn Resorts Ltd.

Wynn Resorts is trending after its recent earnings revealed strong revenue performance driven by robust demand in Macau and Las Vegas, though an earnings miss kept profitability under pressure. The community is actively debating if Macau's sustained recovery and the promising UAE development can ultimately outweigh ongoing concerns about margins.

SSgA Active Trust - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing investor attention amid a noticeable sector rotation away from technology and into areas like energy and defensive stocks. This shift is amplified by varied earnings reports from major tech components and ongoing concerns within the community about the sustainability of AI-driven growth and high capital expenditures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Beacon Harbor Wealth Advisors Inc. Makes New $4.31 Million Investment in Rigel Pharmaceuticals, Inc. $RIGL

Beacon Harbor Wealth Advisors Inc. purchased a new stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing...

Rigel Appoints Michael P. Miller to the Board of Directors

Rigel Appoints Michael P. Miller to the Board of Directors Rigel Appoints Michael P. Miller to the Board of Directors PR Newswire SOUTH SAN FRANCISCO, Calif., Feb. 3, 2026 SOUTH SAN FRANCISCO...

FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?

Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors.

Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded to "Strong Sell" Rating by Zacks Research

Zacks Research lowered shares of Rigel Pharmaceuticals from a "strong-buy" rating to a "strong sell" rating in a report on Tuesday...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Significant Growth in Short Interest

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totaling 3,439,339 shares...

Profound Medical (PROF) Soars 9.5%: Is Further Upside Left in the Stock?

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

HC Wainwright Has Negative Forecast for RIGL FY2026 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Analysts at HC Wainwright lowered their FY2026 earnings per share estimates for Rigel Pharmaceuticals in a research report issued to clients...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the stock...

Rigel Provides Business Update and 2026 Outlook

Rigel Provides Business Update and 2026 Outlook Rigel Provides Business Update and 2026 Outlook PR Newswire SOUTH SAN FRANCISCO, Calif., Jan. 12, 2026 Preliminary fourth quarter 2025 total revenue of...

CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois

Centene expands its Medicaid strategy by partnering with Cityblock Health to serve 10,000 Illinois members with 24/7 wrap-around care.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Stocktwits

Stocktwits Polls

Users question management's transparency and credibility, with some wondering about their approach to new growth opportunities and shareholder communication.

RIGL
Rigel Pharmaceuticals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RIGL News

RIGLRigel Pharmaceuticals